No abstract

Objectıve: Acute Kidney Injury (AKI) and subsequent renal failure are the leading causes of morbidity and mortality in the intensive care unit (ICU). In this study, it was planned to compare Neutrophil Gelatinase-associated Lipocalin (NGAL) and creatinine values in patients diagnosed with AKI and to determine the effect of renal dose dopamine use on renal blood flow, development of chronic renal failure (CRF) and mortality. Materıals and methods: This prospective study was planned with 35 patients developed AKI in the ICU of Bakırköy Dr. Sadi Konuk Training and Research Hospital. The patients were randomized into 2 groups as 18 patients who received dopamine treatment with the recommendation of the cardiology clinic and 17 patients who did not receive dopamine treatment. Urea, creatinine and NGAL plasma levels were compared between groups. Results: There was no difference between the groups in terms of age, gender and AKI stage. The 0th, 24th hour results and 24-hour changes of urea, creatinine and NGAL values of dopamine patient, who took dopamine, were found to be similar to those of patients who did not take dopamine. A significant positive correlation was found between the 24-hour change in creatinine value and the 24-hour change in NGAL (r=0.374; p<0.05). There was no significant change in the diameter and flow of renal arteries between measurements in patients who received dopamine. The rates of patients who regain normal kidney functions, develop CRF or develop mortality between the two groups were found to be similar. Conclusıon: Treatment results of AKI developing in ICU are not satisfactory. Low-dose dopamine treatment has no effect on patient outcomes in these patients. NGAL is a biomarker that has the ability to show renal damage at an early stage. Serial measurement of NGAL concentration during ICU stay may benefit the clinician in early diagnosis and follow-up of AKI.

Objective: Benign prostatic hyperplasia (BPH) affects patients’ quality of life negatively. We aimed to examine the results of prostate artery embolization (PAE) treatment for BPH in the elderly patients with high comorbidity. Materials and Methods: In the present study, we evaluated the patients with lower urinary tract symptoms (LUTS) due to BPH and applied endovascular embolization treatment, who were admitted to our hospital radiology department, between February 2017 and February 2019. Patients with a high risk for surgical operation with an American Society of Anesthesiologists (ASA) score of 3 or above, International Prostate Symptom Score (IPSS) >20 and MR (Magnetic Resonance) prostate volume (PV)>70 cm3 were included in this study. In addition, maximum flow rate Qmaximum (Qmax), MRI PV and IPSS values were recorded in all patients in our clinic before PAE, and the 12th months after PAE. Results: In our study, 15 patients, who had a history of transurethral resection (TUR), and 57-82 years old (mean 73.8), participated. PAE treatment was administered to the patients who were admitted to our hospital with the diagnosis of BPH in patient high comorbidity, LUTS and high risk for open prostatectomy. In our series, Qmax, IPSS, MRI and digital subtraction angiography (DSA) findings were presented. The findings showed that pre-PAE and post-PAE at 12th month, IPSS value 25,13±1,92 and 11,4±6,51 (p=0,001), Qmax; 7,61±3,19 and 16,51±9,56 (p=0,001), MRPV; 135,47±76,48 and 83,27±43,53 (p=0,001) and also all parameters were statistically significant. Conclusion: PAE is a novel treatment modality which is increasingly being used in patients with BPH, and it is an important and effective treatment option since it is much less invasive compared to open surgery, does not require hospitalization after the procedure.

Small renal masses are defined as renal neoplasms with the largest diameter less than 4 cm and the incidence of renal malignancies is increased with the widespread use of cross-sectional imaging methods. One of the options for disease management in small renal masses is ablation therapy. Ablation therapies include options such as radiofrequency ablation, cryoablation and irreversible electroporation. In this review, outcomes and comparisons of ablation therapies used in small renal masses are discussed together with current approaches and studies.